12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Company News  |  Deals

TorreyPines, Eisai deal

TorreyPines sold its preclinical Alzheimer's disease (AD) genetics research program to former partner Eisai for $1.5 million in cash as part of its ongoing restructuring. The program was developed under...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >